Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

Company Overview

Bright Minds Biosciences is a clinical-stage biotechnology company dedicated to the discovery and development of novel small-molecule therapies for neurological and neuropsychiatric disorders. Leveraging a proprietary medicinal chemistry platform, the company designs optimized analogs of naturally occurring compounds and next-generation psychedelics, aiming to improve safety, efficacy and pharmacokinetic profiles compared with first-generation agents.

The company’s pipeline includes lead candidate BMB-101, currently in Phase 2 trials for traumatic brain injury, and BMB-102, which is being evaluated for its potential to enhance neuroplasticity in depressive disorders. In addition, Bright Minds advances preclinical programs targeting cognitive impairment associated with Alzheimer’s disease and stroke recovery. Each program is structured to move rapidly from in vitro screening through clinical proof-of-concept.

Founded in 2017 by a team of neuroscientists and medicinal chemists, Bright Minds Biosciences has assembled a management group with extensive experience in drug discovery, clinical development and regulatory affairs. The executive leadership includes veterans who have guided multiple therapeutic candidates through IND filings, clinical milestones and partnering agreements. The company’s advisory board comprises experts in neurology, psychiatry and pharmaceutical commercialization.

Headquartered in Vancouver, British Columbia, Bright Minds operates research and development facilities in Canada and the United States. The company collaborates with leading academic institutions and contract research organizations across North America and Europe to support its clinical trial activities, imaging studies and formulation development. These strategic partnerships are designed to accelerate the advancement of its pipeline toward regulatory approval and commercial readiness.

Key Stats

• Today's Range: $27.05 to $28.94
• 50-Day Range: $23.27 to $33.00
• 52-Week Range: $0.93 to $79.02
• Volume: 18,963 shs
• Average Volume: 829,088 shs
• Market Capitalization: $199.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $83.25
• Consensus Rating: Buy

Bright Minds Biosciences Stock Analysis - MarketRank™

Bright Minds Biosciences scored higher than 57% of companies evaluated by MarketBeat, and ranked 436th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Bright Minds Biosciences has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bright Minds Biosciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($1.24) to ($3.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bright Minds Biosciences is -78.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bright Minds Biosciences is -78.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bright Minds Biosciences has a P/B Ratio of 30.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.75% of the float of Bright Minds Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Bright Minds Biosciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bright Minds Biosciences has recently increased by 8.54%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bright Minds Biosciences does not currently pay a dividend.

Dividend Growth

Bright Minds Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.75% of the float of Bright Minds Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Bright Minds Biosciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bright Minds Biosciences has recently increased by 8.54%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.04

News Sentiment

Bright Minds Biosciences has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Bright Minds Biosciences this week, compared to 2 articles on an average week.

Search Interest

10 people have searched for DRUG on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.

MarketBeat Follows

6 people have added Bright Minds Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DRUG Stock Analysis - Frequently Asked Questions

How have DRUG shares performed this year?

Bright Minds Biosciences' stock was trading at $36.02 at the beginning of the year. Since then, DRUG stock has decreased by 21.4% and is now trading at $28.30.

How were Bright Minds Biosciences' earnings last quarter?

Bright Minds Biosciences Inc. (NASDAQ:DRUG) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.10.

When did Bright Minds Biosciences' stock split?

Bright Minds Biosciences shares reverse split on Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Bright Minds Biosciences?

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bright Minds Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), ForgeRock (FORG) and SoFi Technologies (SOFI).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRUG
• CIK: 1827401
• Web: brightmindsbio.com
• Phone: 64-7407-2515
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $83.25
• High Stock Price Target: $93.00
• Low Stock Price Target: $75.00
• Potential Upside/Downside: +194.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -14.56%
• Return on Assets: -14.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 126.01
• Quick Ratio: 126.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.92 per share
• Price / Book: 30.76

Miscellaneous

• Outstanding Shares: 7,040,000
• Free Float: 4,039,000
• Market Cap: $199.23 million
• Optionable: Not Optionable
• Beta: -6.01